[Featured Stock] Seegene Soars on News of COVID-19 Diagnostic Reagent Launch
[Asia Economy Reporter Minji Lee] Seegene is experiencing a sharp rise following the news of launching a diagnostic reagent (diagnostic kit) for the novel coronavirus infection (COVID-19) domestically.
At 9:34 AM on the 18th, Seegene was trading at 35,600 KRW on the KOSDAQ market, up 16.15% from the previous session.
Hot Picks Today
Cerebras Soars 70% on IPO Debut: Is Nvidia's Reign Ending as a New AI Semiconductor Power Emerges?
- [Breaking] Samsung Electronics Executives: "We Will Participate Unconditionally... We Urge the Union to Join the Talks"
- "Gave in to the Momentary Temptation": Japanese Police Official Dismissed After Stealing 100 Million Won Next to Body
- "Mom, Isn't It Comfortable Living With Me?"... 'Unexpected Result' Shows Increased Drinking Out of Frustration
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
On the same day, Seegene announced the domestic launch of the COVID-19 diagnostic reagent 'Allplex 2019-nCoV Assay.' This product received European certification (CE-IVD) and emergency use approval from the Ministry of Food and Drug Safety on the 7th and 12th, respectively.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
